T1Type1Cure
Flat lay of medical study desk with a stethoscope, books, and molecular models.
Tara Winstead (Pexels) / Pexels License
Cure & Advancements/April 5, 2025/2 min read

Cell Replacement Therapy Shows Promise in Early Studies—What We Know So Far

Vertex Pharmaceuticals is testing an approach that replaces damaged insulin-producing cells. Early participants have achieved insulin independence, but the therapy is still new and requires careful monitoring.

cure researchbeta cellsadvancements

Key takeaways

  • Vertex is developing a cell replacement strategy that infuses synthesized beta cells into the liver via the portal vein
  • Early study participants have stopped insulin injections and achieved normal blood sugar levels without them
  • The therapy is in early stages and requires low-dose immunosuppression to prevent the body from rejecting the new cells
  • This is not a cure yet—it's a promising experimental treatment that may offer an alternative to daily insulin therapy

A Different Approach: Replacing Beta Cells

Type 1 diabetes damages the beta cells in your pancreas that produce insulin. Rather than trying to fix those damaged cells, Vertex Pharmaceuticals is exploring whether synthetic beta cells can do the job instead.

The approach works by infusing these lab-grown beta cells into the portal vein—a blood vessel that carries blood directly to the liver. Once there, the cells establish themselves and begin producing insulin, glucagon, and other hormones naturally produced by a healthy pancreas.

What Early Results Show

In the early participants treated so far, the results have been striking: blood sugar levels are completely normal without insulin injections. The synthesized cells appear to be functioning like natural beta cells, regulating glucose levels on their own.

These early findings represent a meaningful shift in what's possible for some people with Type 1 diabetes, moving the conversation from managing the disease toward potentially replacing the cells it damages.

The Catch: Immunosuppression

Because the new cells are not the person's own cells, the immune system can recognize them as foreign and attack them. To prevent rejection, participants must take low-dose immunosuppressive medications.

This is an important consideration. While insulin independence is significant, the need for ongoing immunosuppression means this therapy carries different risks and trade-offs than insulin alone. More research is needed to understand the long-term safety and effectiveness of this approach.

Still Very Early

Vertex is currently a leader in this field, but cell replacement therapy remains experimental. The number of people treated so far is small, and we don't yet know how long the benefits will last, how well this works across larger populations, or what the long-term effects of immunosuppression might be.

While early results are encouraging, this is not a cure available today. As with any emerging therapy, much more research and testing are needed before we know whether this approach will become a standard treatment option.

Evidence label

Origin: YouTube / Taking Control Of Your Diabetes® (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.